13F Holdings
中文EN

EXEL EXELIXIS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 939767 · Fiscal year ends 01/01

Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.1%
TTM net income YoY30.6%
TTM EPS YoY40.3%
Revenue 3-yr CAGR12.1%
Net income 3-yr CAGR112.6%

Margins

Gross margin96.3%
Operating margin40.2%
Net margin35.5%
FCF margin46.5%
EBITDA margin41.3%

Returns

ROE44.3%
ROA33.2%
ROIC (approx.)47.8%
Asset turnover0.94x

Leverage & solvency

Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.33x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252026-01-02FY20242025-01-03FY20232023-12-29FY20222022-12-30FY20212021-12-31
Income statement
Revenue$2.32B$2.17B$1.83B$1.61B$1.43B
Cost of revenue$83.70M$76.22M$72.55M$57.91M$52.87M
Gross profit$2.24B$2.09B$1.76B$1.55B$1.38B
R&D expense$825.00M$910.41M$1.04B$891.81M$693.72M
SG&A expense$518.73M$492.13M$542.71M$459.86M$401.71M
Operating income$872.19M$604.62M$170.88M$201.48M$286.67M
Income tax$158.64M$160.37M$49.76M$52.07M$63.09M
Net income$782.57M$521.27M$207.76M$182.28M$231.06M
EBITDA$901.25M$633.42M$196.60M$222.36M$300.30M
EPS (basic)2.881.800.650.570.73
EPS (diluted)2.781.760.650.560.72
Weighted avg. shares (diluted)281.86M296.13M321.46M324.56M322.36M
Balance sheet
Cash & equivalents$482.49M$217.37M$262.99M$502.68M$663.89M
Short-term investments$576.60M$893.90M$732.31M$807.27M$819.90M
Receivables$286.92M$265.44M$237.41M$214.78M$282.65M
Inventory$21.69M$22.39M$17.32M$33.30M$27.49M
Current assets$1.44B$1.47B$1.32B$1.62B$1.83B
PP&E, net$98.96M$119.39M$128.73M$110.62M$104.03M
Goodwill$63.68M$63.68M$63.68M$63.68M$63.68M
Total assets$2.84B$2.95B$2.94B$3.07B$2.62B
Current liabilities$405.64M$403.77M$394.28M$324.36M$337.59M
Total liabilities$683.10M$703.49M$678.45M$583.06M$405.62M
Shareholders' equity$2.16B$2.24B$2.26B$2.49B$2.21B
Shares outstanding262.48M281.73M302.79M323.95M318.84M
Cash flow statement
Operating cash flow$884.27M$699.97M$333.32M$362.61M$400.80M
Capital expenditure$8.43M$28.43M$40.47M$27.71M$54.23M
Free cash flow$875.84M$671.54M$292.86M$334.91M$346.58M
Investing cash flow$350.44M-$116.78M-$26.95M-$524.41M-$42.88M
Financing cash flow-$969.59M-$628.81M-$546.05M$586,000-$14.80M
Depreciation & amortization$29.05M$28.80M$25.72M$20.88M$13.63M
Stock-based compensation$112.98M$93.84M$106.34M$107.57M$119.82M
Share buybacks$947.51M$652.03M$550.38M$0$0

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.